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Abstract  
Objective: The Manhattan Lupus Surveillance Program (MLSP) is a population-based 
registry designed to determine the prevalence of Systemic Lupus Erythematosus (SLE) 
in 2007 and incidence from 2007 to 2009 among Manhattan residents and characterize 
cases by race/ethnicity, including Asians and Hispanics for whom data are lacking. 
Methods: We identified possible SLE cases from hospitals, rheumatologists, and 
administrative databases and defined cases using the American College of 
Rheumatology (ACR) classification criteria, the Systemic Lupus International 
Collaborating Clinics (SLICC) classification criteria, or a treating rheumatologist’s 
diagnosis. Rates among Manhattan residents were age-standardized, and capture-
recapture (C-RC) analyses were conducted to assess case under-ascertainment.   
Results: By the ACR definition, the age-standardized prevalence and incidence rates of 
SLE were 62.2 and 4.6 per 100,000 person-years. Rates were approximately nine times 
higher in women than men for prevalence (107.4 vs. 12.5) and incidence (7.9 vs. 1.0). 
Compared with non-Hispanic (NH) white women (64.3), prevalence was higher among 
NH-black (210.9), Hispanic (138.3), and NH-Asian women (91.2). Incidence rates were 
higher among NH-black women (15.7) compared with NH-Asian (6.6), Hispanic (6.5), 
and NH-white women (6.5). C-RC adjustment increased prevalence and incidence rates 
(75.9 and 6.0). Alternate SLE definitions without C-RC adjustment found higher age-
standardized prevalence and incidence rates (SLICC: 73.8 and 6.2; rheumatologist: 
72.6 and 5.0) than the ACR definition, with similar patterns by sex and race/ethnicity.   
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Conclusion: The MLSP confirms findings from other registries on disparities by sex 
and race/ethnicity, provides new estimates among Asians and Hispanics, and also 
provides estimates using the SLICC criteria.  
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Introduction: 
 Systemic Lupus Erythematosus (SLE) is a potentially fatal, heterogeneous, chronic, 
systemic autoimmune disease of unknown etiology [1]. Given widely varying estimates 
of the incidence and prevalence of SLE in the United States (US) [2] and the absence of 
data available for certain demographic groups, we sought to obtain a fundamental 
epidemiologic understanding of SLE across racial/ethnic groups. Under the auspices of 
the National Arthritis Action Plan [3], the Centers for Disease Control and Prevention 
(CDC) funded four state or city health departments as well as the Indian Health Service 
(IHS) to more robustly define the incidence and prevalence of SLE. Results from the 
two initial sites, the Georgia Lupus Registry (GLR) and the Michigan Lupus 
Epidemiology and Surveillance Program (MILES Program), and the IHS site have been 
recently published [4-6]. However, their estimates for Asians and Hispanics were 
limited. The Manhattan Lupus Surveillance Program (MLSP) was designed, along with 
the California Lupus Surveillance Project (CLSP), to provide estimates of the incidence 
and prevalence of SLE overall and specifically among Hispanic and Asian populations.  
 We launched the MLSP in 2009 as a collaboration between the New York City 
Department of Health and Mental Hygiene (DOHMH) and New York University School 
of Medicine (NYUSoM). Following methods similar to those of the other CDC-funded 
sites [2, 5, 6], we designed the MLSP as a retrospective descriptive project to identify all 
cases of diagnosed SLE among Manhattan residents from 2007 to 2009 to determine 
the prevalence and incidence of SLE in this population. 
Patients and Methods 
The Manhattan Lupus Surveillance Program 
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 The MLSP was designed to be similar to the GLR and MILES program and, as 
described elsewhere [5, 6], was conducted as a public health surveillance project by the 
DOHMH with NYUSoM acting as a public health agent on behalf of the DOHMH. No 
patients were contacted for this project. Medical records were collected under the health 
surveillance exemption to the Health Insurance Portability and Accountability Act 
(HIPAA) privacy rules (45 CFR § 164.512(b)) and as authorized by New York City 
Charter Sections 556(c)(2) and (d)(2). The CDC deemed the MLSP public health 
practice not requiring review by the CDC Institutional Review Board (IRB). IRBs at both 
the DOHMH and NYUSoM reviewed and deemed the MLSP a surveillance activity. 
Additional IRB applications were completed and submitted to independent case finding 
sources as requested.  
Study Population and Period 
 The MLSP surveillance period was January 1, 2007, through December 31, 2009. 
Manhattan was selected as the program catchment area due to its racial/ethnic diversity 
and because it is an island on which inhabitants largely remain for their health care, 
thus making access to medical records easier. We used data from specialty lupus 
clinics across NYC during initial planning for the MLSP and found that few Manhattan 
residents seek care in outer boroughs and that residents from other boroughs were 
more likely to seek care across a wide geographic range. Based on United States 
Census data, there were 1,611,581 persons residing in Manhattan in 2010 (48% non-
Hispanic (NH) white, 13% NH-black, 25% Hispanic, 11% NH-Asian) [7].  
Case Definitions 
Page 6 of 60
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
7 
 
Our primary American College of Rheumatology (ACR) case definition required > 
4 of 11 ACR classification criteria for SLE [8, 9]. Under the ACR classification criteria, 
patients with evidence of lupus nephritis (by biopsy report or specific documentation by 
a rheumatologist and/or nephrologist) are considered to have met renal criteria for SLE, 
even without information on the degree of proteinuria or description of the sediment. We 
also used two secondary case definitions for SLE: 1) the Systemic Lupus 
Erythematosus Collaborating Clinics (SLICC) classification criteria, which requires a 
case to have at least four criteria, including at least one clinical and one immunologic 
criterion or having biopsy-proven lupus nephritis in the presence of antinuclear 
antibodies or anti-double-stranded DNA antibodies, or 2) a treating rheumatologist’s 
diagnosis of SLE. The SLICC case definition was included as a recently derived 
classification criteria with greater sensitivity and less specificity than the ACR 
classification criteria [10]. The rheumatologist case definition was included because 
there is no gold standard for diagnosing SLE and diagnosis is usually made by a 
physician familiar with the disease, often a rheumatologist. 
Initial Case Finding  
 
We used information from administrative databases, hospitals, and private 
rheumatologists to identify possible cases from as far back as 2004 when records were 
available. Administrative databases included the New York State Department of Health 
Statewide Planning and Research Cooperative System with information on 
hospitalization discharges in New York State and DOHMH Vital Records with 
information on all deaths in NYC. We included only hospitals and private 
rheumatologists based in Manhattan. We queried these sources to identify records with 
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International Classification of Disease (Ninth Revision, Clinical Modification) diagnosis 
codes indicating SLE (710.0), discoid lupus (695.4), or a related condition that may 
evolve into SLE or have related symptoms (710.8, other specified connective tissue 
disease; 710.9, unspecified connective tissue disease; 710.2, Sicca syndrome). If 
residence information was available from the case finding source, we further restricted 
these records to include only those with evidence of Manhattan residence. Final 
screening of records was completed by trained MLSP abstractors to confirm physician 
diagnosis or suspicion of SLE or a related connective tissue disease and Manhattan 
residence during the surveillance period.  
Data collection 
After initial case finding, abstractors collected and entered information from the 
medical records into a DOHMH database, with database and data dictionary materials 
adapted from those used by the GLR. When necessary, we corroborated Manhattan 
residence using the LexisNexis on-line database service [11]. Our abstractors entered 
any ambiguous information into open text notes which were later reviewed with the 
NYUSoM principal investigator to correctly code in the database.  
All MLSP abstractors were trained under the GLR model [5] before abstraction 
began and underwent routine quality assurance reviews throughout the project. These 
reviews provided the opportunity for abstractors and the NYUSoM principal investigator 
to discuss any issues arising in the field and to address questions from the abstractors. 
Each abstractor had a medical degree and consistently achieved the required minimum 
inter-observer agreement of 90% on all elements and 95% on ACR classification criteria 
using abstraction by the NYUSoM principal investigator as the gold standard. The 
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average performance of the abstractors during training and reviews was 95.6% on all 
elements, 97.2% on ACR classification criteria elements, and 97.5% on the unique 
elements in the SLICC classification criteria that were not already captured as part of 
the ACR classification criteria.  
Statistical Analysis 
We defined prevalent cases as new or existing cases meeting the ACR, SLICC, 
or rheumatologist case definition and residing in Manhattan at some time from January 
1, 2007, through December 31, 2007. We defined incident cases as those meeting at 
least one of the case definitions, first diagnosed from January 1, 2007, through 
December 31, 2009, and residing in Manhattan. Population denominators were taken 
from the DOHMH interpolated intercensal population estimates for Manhattan [12]. We 
calculated rates overall, by sex, and by race/ethnicity per 100,000 person-years and 
age-standardized to the United States 2000 standard population using 10 year age 
groups for each racial/ethnic group [13]. Information on race was collected separately 
from Hispanic ethnicity during abstraction. For analysis, we assigned cases to one of 
five mutually exclusive race/ethnicity categories: NH-whit , NH-black, NH-Asian, 
Hispanic, and NH-other. NH-cases identified with more than one race were categorized 
as other.   
We conducted capture-recapture (C-RC) analyses [14, 15] to estimate case 
under-ascertainment from our primary ACR case definition. We fit log-linear models 
separately for incident and prevalent cases by sex and race/ethnicity to estimate the 
number of cases missed in our catchment area. Specifically, we fit various models that 
addressed potential violation of the homogeneity assumption of capture probability and 
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identified the best fitting model using the Akaike Information Criteria. We then used 
estimates from these models to calculate revised prevalence and incidence rates. 
 We used chi-square tests, or Fisher’s exact tests when needed, to assess 
univariate differences in SLE and ACR manifestations by race/ethnicity and sex. We 
compared differences between estimates by case definition using 95% confidence 
intervals (CIs) of the age-standardized rates, with non-overlapping CIs considered to be 
significantly different. All analyses were completed using SAS version 9.3 (SAS Institute 
Inc., Cary, NC, USA) and R version 3.3.0 (R Foundation for Statistical Computing, 
Vienna, Austria). 
Results: 
 
Case Finding 
 
Case finding and abstraction was completed in 19 out of 21 hospitals (90.5%, 
Figure 1), with two hospitals declining to participate (a cancer specialty hospital, and a 
Veteran’s Administration Hospital). Case finding and abstraction was performed from 
records of 94 out of 124 (75.8%) private rheumatologists identified in the catchment 
area. Of the 30 rheumatologists who did not participate, 19 did not respond to repeated 
requests or declined to participate, two died, two had retired and relocated, and seven 
agreed to participate but abstraction could not be arranged despite repeated attempts 
before data abstraction ended.  
Initial lists provided from the various case finding sources identified 76,220 
records (Figure 1). We deduplicated and removed records that did not have a 
Manhattan address, resulting in 5,065 possible cases with records for abstraction. 
During abstraction and data cleaning, we deemed 1,184 cases ineligible due to 
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miscoded diagnosis or non-Manhattan residence. Of the remaining 3,881 possible 
cases, 1,859 met at least one of the case definitions.    
Primary ACR Case Definition: Prevalence  
 
In 2007 a total of 1,078 cases (307 NH-white, 282 NH-black, 344 Hispanic, 111 
NH-Asian, and 34 NH-other race/ethnicity) fulfilled the ACR case definition for SLE 
(Table 1). The overall crude and age-standardized prevalence was 68.2 (95% CI 64.1-
72.2) and 62.2 (95% CI 58.4-66.0) per 100,000 person-years. Age-standardized rates 
were approximately nine times higher for women compared with men (107.4 vs. 12.5). 
Age-standardized rates also differed by race/ethnicity among both women and men. 
The highest age-standardized prevalence was seen among NH-black women (210.9) 
followed by Hispanic women (138.3), NH-Asian women (91.2), and NH-white women 
(64.3). The age-standardized prevalence among men followed a similar pattern with the 
highest estimate among NH-blacks (26.7) followed by Hispanics (19.4), NH-Asians 
(14.2), and NH-whites (3.7). C-RC estimated an additional 122 cases of SLE, indicating 
that 10% of cases may have been missed. Almost two-thirds (62.5%) of the estimated 
cases missed were NH-white women. With C-RC adjustment, the prevalence increased 
to 75.9 per 100,000 person-years (95% CI 70.6-81.2).  
The average age (± standard deviation [SD]) among women and men with SLE 
living in Manhattan in 2007 was 43.3 (± 15.5) and 40.7 (± 16.9) years respectively. The 
average age by race/ethnicity was 47.0 (± 16.5) years among NH-whites, 42.9 (± 15.6) 
years among Hispanics, 41.5 (± 13.7) years among NH-blacks, and 37.3 (± 15.4) years 
among NH-Asians. Figures 2A shows age-specific prevalence for women by 
race/ethnicity. Prevalence was higher among NH-black and Hispanic women ages 20 to 
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59 years old compared to similarly-aged NH-white women. Prevalence among NH-
Asian women was not significantly different than those among NH-white women for any 
age group. Numbers among men were too small to assess age-specific rates by 
race/ethnicity. 
  Among the 344 Hispanic cases, 82.9% were also identified as white, 11.3% as 
black, and 5.8% as other race/ethnicity. Information on Hispanic ethnicity was often 
absent, with 239 (69.5%) having no further details, but Hispanic case ethnicities 
included Central or South American, Cuban, Dominican, Mexican, Puerto Rican, and 
Spanish. There were 111 NH-Asian cases as well as five identified as NH-other due to 
multiple race/ethnicity but with evidence of Asian race. More than a quarter (26.7%) of 
these cases had no further classification for Asian ethnicity, but ethnicities among cases 
with information available included Chinese, Filipino, Hawaiian, Indian or Pakistani, 
Japanese, Korean, Pacific Islander not otherwise specified, South Asian, and 
Vietnamese.   
 Table 2 shows the occurrence of the 11 ACR criteria overall and by race/ethnicity 
among prevalent ACR cases. Renal disease was more common among NH-Asians 
(53.2%), NH-blacks (50.7%), and Hispanics (49.4%) compared with NH-whites (25.4%). 
Neurologic manifestations were more common among Hispanics (26.2%) and NH-
blacks (24.5%) compared with NH-whites (16.6%). Also compared with NH-whites, 
discoid lesions were more commonly seen among NH-blacks (25.9% vs. 8.8%) and 
malar rash was more commonly seen among Hispanics (50.0% vs. 35.8%).  
Primary ACR Case Definition: Incidence Rates 
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From 2007-2009, 232 incident cases met the ACR case definition (Table 3) for 
SLE (92 NH-white, 62 NH-black, 49 Hispanic, 22 NH-Asian, and 7 NH-other 
race/ethnicity). The overall crude and age-standardized incidence rates were 4.9 (95% 
CI 4.3-5.5) and 4.6 (95% CI 4.0-5.2) per 100,000 person-years respectively. Age-
standardized rates differed by sex, and were almost 8 times higher for women 
compared with men (7.9 vs. 1.0). Age-standardized rates also differed by race/ethnicity 
among both women and men. The highest age-standardized incidence rates among 
women were among NH-blacks (15.7) followed by NH-Asians (6.6), Hispanics (6.5), and 
NH-whites (6.5). Similarly, the highest age-standardized incidence rates among men 
were among NH-blacks (2.4) followed by Hispanics (1.3), NH-Asians (0.5), and NH-
whites (0.5). C-RC adjustment estimated 284 incident cases of SLE, indicating that 18% 
of cases were missed and 67.0% of these were NH-white women. The resulting C-RC 
adjusted incidence rate increased to 6.0 per 100,000 person-years (95% CI 4.6-7.4).  
The average age (±SD) at diagnosis was 40.4 (± 16.6) years among women and 
42.9 (± 20.4) years among men. The average age (±SD) at diagnosis was 42.2 (± 17.7) 
years among NH-whites, 39.2 (± 16.6) years among NH-blacks, 39.6 (± 17.0) years 
among Hispanics, and 37.9 (± 16.0) years among NH-Asians. Figure 2B shows age-
specific incidence rates for women by race/ethnicity. The only age-specific difference 
was between NH-black and NH-white women aged 20 to 39 years old. Otherwise, due 
to small numbers within each strata, no age-specific differences were found. 
  Among the 49 incident Hispanic cases, 77.6% were also identified as NH-white, 
16.3% as NH-black, and 6.1% as NH-other race/ethnicity. As with prevalent cases, 
Hispanic ethnicity information for incident cases was often absent, with 71.4% having no 
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further ethnicity information available.  Among the 22 incident NH-Asian cases, 32% 
had no further data available.  
Table 2 shows the occurrence of the 11 ACR criteria overall and by race/ethnicity 
among incident ACR cases. Evidence of renal disease was found among 34.9% of 
incident cases, but was more common among NH-Asians (45.5%), NH-blacks (43.5%), 
and Hispanics (42.9%) compared with NH-whites (23.9%). Discoid lesions were more 
common among NH-blacks (25.8%) compared with NH-whites (9.8%). 
Secondary Case Definitions 
 Prevalence and incidence rates calculated using the SLICC case definition for 
SLE were significantly higher than those calculated with the primary case ACR 
definition. Using the SLICC case definition generated crude and age-standardized 
prevalence of 80.1 (95% CI 75.7-84.5) and 73.8 (95% CI 69.6-77.9) per 100,000 years 
respectively, which were 17-19% higher than those calculated with the ACR case 
definition. The SLICC crude and age-standardized incidence rates (6.6, 95% CI 5.8-7.3; 
6.2, 95% CI 5.5-6.9) were nearly 35% higher than the ACR incidence rates.  
The rheumatologist case definition yielded crude and age-standardized 
prevalence that was approximately 17% higher than those from the ACR case definition 
(79.4, 95% CI 75.0-83.8; 72.6, 95% CI 68.5-76.7). Crude and age-standardized 
incidence rates using the rheumatologist case definition were similar to rates using the 
ACR case definition (5.3, 95% CI 4.7-6.0; 5.0, 95% CI 4.4-5.7). For both secondary 
case definitions differences in rates by sex and race/ethnicity were similar to those 
identified by the ACR case definition.  
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 Of the 1,538 incident and prevalent cases meeting either the ACR or SLICC case 
definition, 75.6% met both ACR and SLICC definitions, 4.3% only met the ACR 
definition, and 20.2% met the SLICC definition only. Table 4 displays information on the 
unique SLICC criteria that are not part of the ACR classification criteria among incident 
and prevalent cases meeting the SLICC case definition only. The most common unique 
SLICC criteria among these cases were low complement levels, alopecia, and different 
definitions for lymphopenia. In addition, 5.5% of cases meeting the SLICC case 
definition had an ANA and/or anti–double-stranded DNA antibody and a biopsy 
consistent with lupus nephritis. Reasons that cases met the ACR and not the SLICC 
case definition were largely due to having > 4 clinical criteria but no immunologic 
criteria, differences in categorization of photosensitivity and malar rash (which were 
separated in the ACR and combined in the SLICC criteria), and differences in defining 
lymphopenia and anti-cardiolipin antibody (data not shown).    
Discussion 
Our analysis of the MLSP provides prevalence and incidence rate estimates of 
SLE among Manhattan residents using methods similar to other CDC-funded SLE 
registries. Our analysis confirms evidence for higher prevalence of SLE among NH-
blacks compared with NH-whites and adds evidence for higher prevalence of SLE 
among Hispanics and NH-Asians as well. The MLSP is also the first among the CDC-
funded SLE registry sites to report using the SLICC classification criteria, which were 
recently validated, to describe cases of SLE [10]. 
The age-standardized prevalence and incidence of SLE in Manhattan were 62.2 
(95% CI 58.4-66.0) and 4.6 (95% CI 4.0-5.2) using the ACR case definition. Compared 
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with previous reports by the CDC-funded sites , we estimated slightly lower overall age-
standardized prevalence than the GLR (73.0, 95% CI 68.9-77.4) [5] and MILES (72.8, 
95% CI 70.8-74.8) [6], but found similar disparities by sex and race/ethnicity for NH-
whites and NH-blacks. MLSP prevalence estimates increased with C-RC adjustment 
and were comparable to C-RC adjusted estimates from the GLR (75.8, 95% CI 70.3-
81.2 vs. 83.0, 95% CI 78.6-87.7).  Our age-standardized incidence rates using the ACR 
case definition were similar to those from the GLR and MILES. 
We found the highest prevalence and incidence rates among NH-blacks, in line 
with the GLR and MILES and with preliminary data from the CLSP. However, unlike the 
GLR and MILES we found elevated prevalence among NH-Asians and Hispanics 
compared with NH-whites. Compared with preliminary crude estimates from the CLSP 
[16] the MLSP showed similar elevated rates among Hispanics (84.2, 95% CI 75.3-93.1 
vs 87.7 95% CI 72.1-106.8) but slightly lower rates among NH-Asians (64.0, 95% CI 
52.1-75.9 vs 95.8 95% CI 84.9-108.1). These MLSP findings are particularly important, 
given the few published studies on prevalence and incidence of SLE among Asians and 
Hispanics in the United States. A 1973 review presented estimates among NYC 
residents from 1956 to 1965 but focused only on whites, blacks, and Puerto Ricans [17]. 
Another study published in 2001 estimated the prevalence of SLE among Hispanics in 
Arizona to be 103 per 100,000, slightly higher than the rate found by the MLSP among 
Hispanics in Manhattan [18]. A more recent study using Medicaid data estimated an 
even higher prevalence of SLE among Hispanics (126.5 per 100,000) with Medicaid 
coverage in the United States from 2000 to 2004 [19].  
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The study using Medicaid data is one of the few to estimate rates of SLE among 
Asians in the United States, reporting a prevalence almost four times that estimated by 
the MLSP (175.1 per 100,000 vs. 45.7) [19]. The only other studies known to assess 
rates SLE among Asians in the United States focused on SLE prevalence. One study 
identified cases in Hawaii based on physician diagnosis at five medical centers and 
outpatient practices in 1989. The overall SLE prevalence identified in that study (41.8 
per 100,000) was similar to the MLSP estimate for NH-Asians, and the age-
standardized rates for women from specific Asian ethnic groups (Chinese, Filipino, 
Hawaiian, Japanese) was found to be higher compared with that among white women 
[20]. Another study, using hospital discharge data, reported that Asian/Pacific Islander 
women had a lower rate of prevalent SLE compared with white women [21]. Less is 
known about the incidence of SLE among Asians. In England, new diagnoses of SLE 
are more common among Asians, specifically South Asians from India and Pakistan, 
compared with whites [22, 23], but to our knowledge there are no other published 
reports on the incidence of SLE among Asians in the United States.   
In this analysis, we also provide information on manifestations among SLE 
cases. Clinical or serologic manifestations among prevalent cases approximated those 
from the GLR and MILES registries. The MLSP found a high burden of nephritis overall 
with nearly half (42.4%) of prevalent cases developing nephritis. The proportion of those 
with nephritis was higher among non-white prevalent cases, specifically 50.7% among 
NH-blacks, 49.4% among Hispanics, and 53.2% among NH-Asians, compared with 
25.4% among NH-whites, in line with other studies [5, 6, 19, 24, 25].    
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The SLICC case definition for SLE yielded higher incidence and prevalence 
estimates than the ACR case definition. Unique criteria which substantiated the 
classification of SLE based on SLICC but not ACR criteria, included low complements, 
alopecia, and different definitions for lymphopenia [10]. The small number of cases that 
met the ACR but not the SLICC case definition is reassuring as it suggests that few 
cases met ACR criteria for SLE without the presence of autoantibodies. However, given 
the descriptive nature of the MLSP and the absence of a gold standard test that would 
unambiguously identify SLE, this project cannot assess which set of classification 
criteria is more sensitive or specific. In addition, non-overlapping confidence intervals 
were used to conservatively assess differences among rates (26).  
There were several limitations to this project. First, we may have underestimated 
cases as two hospitals and one quarter of rheumatologists in the catchment area 
declined to participate. Most of the practices that did not participate were in 
neighborhoods with a majority white population, which is in line with our C-RC analysis 
that estimated 67.3% of prevalent cases and 70.0% of incident cases missed were NH-
white. However, the exclusion of the Veteran’s Administration Hospital may have 
resulted in under-identification of males diagnosed with SLE. We also did not include 
nephrology, dermatology, or primary or alternative care practices among our case 
finding sources. Though when possible we did query hospital pathology databases for 
relevant kidney or skin biopsies, we still may have missed milder cases that were not 
hospitalized or seen by a rheumatologist during the surveillance period. It is also 
possible that we missed cases if they lived in Manhattan but sought care in other 
boroughs or a neighboring state. 
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Second, medical systems differed tremendously, and any difficulty navigating 
different electronic medical records or with the legibility of paper charts could have led 
to missed or miscoded data. Additionally, medical records are designed for physician 
use, not for data abstraction and surveillance. Thus, some information of interest may 
have been missing or ambiguous, depending on what was collected and recorded by 
the case finding source.  
Third, abstracting occurred several years after the surveillance period, which 
could have led to missing information if records were put into storage or data elements 
were lost during a facility’s migration from paper to electronic records. This lag time may 
have also affected our ability to find all prevalent cases of SLE, as some newer systems 
were unable to query past certain dates. Additionally, many private practices did not 
retain information on patients’ prior addresses, so we may not have abstracted cases 
who moved outside of Manhattan since the surveillance period. However, when 
possible the software LexisNexis was used to verify patient residence within the 
catchment area.  
Finally, data on race and ethnicity was abstracted from administrative and 
medical records, which may not accurately represent the patient’s own racial or ethnic 
identification. Additionally, information on ethnicity was often missing or did not include 
detail such as country of origin, which limited our ability to describe rates of SLE among 
specific ethnic groups. Though available information did reflect the major ethnic groups 
in Manhattan, ethnicity information was missing for most Hispanic cases and more than 
one quarter of NH-Asian cases. Categorized broadly, Hispanic or Asian race 
encompasses a number of heterogeneous groups and SLE rates among them may 
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differ. Given the already limited number of published studies on SLE among Asians and 
Hispanics, additional work is needed to better describe and understand the experience 
of SLE among specific ethnic subpopulations.  
Despite these limitations, our analysis benefitted from the design and 
composition of the MLSP. First, the MLSP was designed as a population-based registry 
with methods similar to four other CDC-funded SLE registries, which allowed us to 
compare rates across sites. Second, the diverse population within our catchment area 
allowed us to estimate rates of SLE among the major racial categories, particularly 
Asians and Hispanics. Third, given the recent publication of the SLICC classification 
criteria, we were able to estimate rates of SLE by this case definition and compare them 
to the ACR case definition. Fourth, the partnership with the DOHMH allowed us to 
collect information from a number of case finding sources and find complete clinical 
information on most cases. Finally, our abstractors all had a medical background, which 
helped during training and also provided an advantage during extensive review of 
medical records to identify SLE criteria. 
In conclusion, we found substantial disparities in prevalence, incidence, and 
manifestations of SLE by sex and race/ethnicity among Manhattan residents. Women 
consistently had higher prevalence and incidence rates of SLE compared with men, and 
NH-blacks, Hispanics, and NH-Asians had higher rates of diagnosed SLE and a higher 
proportion lupus nephritis compared with NH-whites. The highest rates of SLE were 
seen among NH-black women followed by Hispanic, NH-Asian, and NH-white women. 
Using the SLICC criteria for SLE provided higher prevalence and incidence rates than 
the ACR criteria. 
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Table 1: Crude and age-standardized prevalence of SLE among Manhattan residents, 2007, according to the ACR, SLICC, and rheumatologist case 
definitions overall and by race/ethnicity and sex 
 ACR  SLICC Rheumatologist 
N Crude 
rate 
(95% CI) 
Age-
standardized 
rate (95% CI) 
Capture-recapture  N Crude 
rate 
(95% CI) 
Age-
standardized 
rate (95% CI) 
N Crude 
rate 
(95% CI) 
Age-
standardized 
rate (95% CI) 
N 
missed 
Adjusted 
rate 
(95% CI) 
Overall 1,078 68.2 
(64.1-
72.2) 
62.2 (58.4-
66.0) 
122.4 75.9 
(70.6-
81.2) 
1,267 80.1 
(75.7-
84.5) 
73.8 (69.6-
77.9) 
1,256 79.4 
(75.0-
83.8) 
72.6 (68.5-
76.7) 
Male 101 13.6 
(10.9-
16.2) 
12.5 (10.0-
15.0) 
8.3 14.7 
(12.5-
16.9) 
110 14.8 
(12.0-
17.6) 
13.8 (11.1-
16.4) 
98 13.2 
(10.7-
16.1) 
12.0 (9.7-14.7) 
Female 977 116.7 
(109.3-
124.0) 
107.4 (100.5-
114.4) 
114.1 130.3 
(122.1-
138.4) 
1,157 138.2 
(130.2-
146.1) 
128.3 (120.7-
135.9) 
1,158 138.3 
(130.3-
146.2) 
127.5 (119.9-
135.1) 
Non-
Hispanic 
White 
307 40.5 
(36.0-
45.0) 
34.7 (30.7-
38.8) 
389.4 51.4 
(45.0-
57.7) 
373 49.2 
(44.2-
54.2) 
42.7 (38.1-
47.3) 
352 46.4 
(41.6-
51.3) 
39.7 (35.3-
44.0) 
Male 17 4.7 (2.7-
7.5) 
3.7 (2.2-6.0) 22.9 6.3 (3.2-
9.4) 
23 6.3 (4.0-
9.5) 
5.3 (3.3-8.0) 24 6.6 (4.2-
9.8) 
5.3 (3.4-7.8) 
Female 290 73.4 
(64.9-
81.8) 
64.3 (56.4-
72.2) 
366.5 92.7 
(83.4-
102.1) 
350 88.6 
(79.3-
97.8) 
78.2 (69.4-
86.9) 
328 83.0 
(74.0-
92.0) 
72.0 (63.7-
80.4) 
Non-
Hispanic 
Black 
282 131.4 
(116.1-
146.8) 
124.9 (110.3-
139.6) 
285.6 133.1 
(130.6-
135.7) 
326 151.9 
(135.5-
168.4) 
144.7 (128.9-
160.5) 
312 145.4 
(129.3-
161.6) 
137.7 (122.3-
153.1) 
Male 28 28.5 
(18.9-
41.2) 
26.7 (17.7-
38.7) 
28.0 28.5 
(28.1-
28.9) 
31 31.6 
(21.4-
44.8) 
29.7 (20.2-
42.3) 
24 24.4 
(15.7-
36.4) 
22.6 (14.5-
33.7) 
Female 254 218.4 
(191.5-
245.2) 
210.9 (184.8-
237.1) 
257.6 221.4 
(217.1-
225.8) 
295 253.6 
(224.7-
282.5) 
244.4 (216.3-
272.6) 
288 247.6 
(219.0-
276.2) 
237.2 (209.5-
264.8) 
Hispanic 344 84.2  
(75.3-
93.1)  
82.8 (74.0-
91.7) 
345.4 84.6 
(83.8-
85.3) 
372 91.1 
(81.8-
100.3) 
90.2 (81.0-
99.5) 
396 97.0 
(87.4-
106.5) 
96.2 (86.7-
105.8) 
Male 38 19.7 
(13.9-
27.0)  
19.4 (13.6-
26.9) 
38.1 19.7 
(19.4-
20.0) 
38 19.7 
(13.9-
27.0) 
19.5 (13.7-
26.9) 
33 17.1 
(11.8-
24.0) 
16.7 (11.4-
23.6) 
Female 306 142.1 
(126.2-
158.0)  
138.3 (122.7-
153.9) 
307.3 142.7 
(141.5-
143.9) 
334 155.1 
(138.4-
171.7) 
151.7 (135.3-
168.1) 
363 168.5 
(151.2-
185.9) 
165.3 (148.2-
182.5) 
Non-
Hispanic 
Asian 
111 64.0 
(52.1-
75.9)  
56.2 (44.7-
67.7) 
131.0 75.5 
(66.0-
85.0) 
145 83.6 
(70.0-
97.2) 
75.1 (61.7-
88.5) 
118 68.0 
(55.7-
80.3) 
62.2 (49.7-
74.6) 
Male 15 19.3 
(10.8-
31.9)  
14.2 (7.6-24.0) 17.3 22.3 
(17.0-
27.6) 
15 19.3 
(10.8-
31.9) 
14.2 (7.6-24.0) 13 16.8 
(8.9-
28.7) 
12.5 (6.2-22.6) 
Female 96 100.0 
(81.0-
122.2) 
91.2 (72.1-
113.8) 
113.7 118.5 
(105.6-
131.3) 
130 135.5 
(112.2-
158.7) 
125.9 (102.0-
149.9) 
105 109.4 
(88.5-
130.3) 
103.6 (81.5-
125.8) 
Non-
Hispanic 
Other 
34   49.0  51   78   
Case definitions: ACR: meet ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE; SLICC: have sufficient criteria to meet 
the Systemic Lupus Erythematosus Collaborating Clinics (SLICC) classification; Rheumatologist: have been diagnosed with SLE by a treating 
rheumatologist  
Rates are per 100,000 Manhattan resident person-years. Denominator data is based on 2007 intercensal population estimates from the NYC 
DOHMH Bureau of Epi Services (2000-2014 files). Data are standardized for age and race/ethnicity to the US 2000 Standard Population. Cases were 
assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-Hispanic black, non-Hispanic Asian, Hispanic, and 
non-Hispanic other. Non-Hispanic cases identified with more than one race were categorized as non-Hispanic other.   
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Table 2: Frequency of 11 ACR manifestations of SLE among prevalent and incident cases by the ACR case definition, 
overall and by race/ethnicity 
 Prevalent cases (2007) Incident cases (2007-2009) 
 Overall Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Hispanic Non-
Hispanic 
Asian 
Overall Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Hispanic Non-
Hispanic 
Asian 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Overall 1,078 307 
(28.5) 
282 
(26.2) 
344 
(31.9) 
111 
(10.3) 
232 92 
(39.7) 
62 
(26.7) 
49 
(21.1) 
22 (9.5) 
Antinuclear 
antibody 
 
996 
(92.4) 
284 
(92.5) 
262 
(92.9) 
316 
(91.9) 
103 
(92.8) 
213 
(91.8) 
82 
(89.1) 
58 
(93.5) 
47 
(95.9) 
22 
(100.0) 
Hematologic 
disorder 
 
893 
(82.8) 
255 
(83.1) 
238 
(84.4) 
278 
(80.8) 
98 
(88.3) 
188 
(81.0) 
71 
(77.2) 
56 
(90.3*) 
37 
(75.5) 
19 
(86.4) 
Arthritis 813 
(75.4) 
 
246 
(80.1) 
204 
(72.3) 
255 
(74.1) 
80 
(72.1) 
159 
(68.5) 
66 
(71.7) 
41 
(66.1) 
30 
(61.2) 
17 
(77.3) 
Immunologic 
disorder 
 
781 
(72.4) 
213 
(69.4) 
204 
(72.3) 
253 
(73.5) 
89 
(80.2*) 
170 
(73.3) 
66 
(71.7) 
46 
(74.2) 
37 
(75.5) 
18 
(81.8) 
Renal 
disorder 
 
457 
(42.4) 
 
78 
(25.4) 
143 
(50.7*) 
170 
(49.4*) 
59 
(53.2*) 
81 
(34.9) 
22 
(23.9) 
27 
(43.5*) 
21 
(42.9*) 
10 
(45.5*) 
Serositis 449 
(41.7) 
 
117 
(38.1) 
127 
(45.0) 
156 
(45.3) 
36 
(32.4) 
84 
(36.2) 
25 
(27.2) 
33 
(53.2*) 
18 
(36.7) 
5 (22.7) 
Malar rash 428 
(39.7) 
 
110 
(35.8) 
82 
(29.1) 
172 
(50.0*) 
46 
(41.4) 
86 
(37.1) 
31 
(33.7) 
20 
(32.3) 
22 
(44.9) 
8 (36.4) 
Photo 
sensitivity 
370 
(34.3) 
 
121 
(39.4) 
76 
(27.0*) 
132 
(38.4) 
30 
(27.0*) 
74 
(31.9) 
32 
(34.8) 
11 
(17.7*) 
21 
(42.9) 
7 (31.8) 
Oral ulcers 333 
(30.9) 
 
104 
(33.9) 
64 
(22.7*) 
115 
(33.4) 
37 
(33.3) 
81 
(34.9) 
42 
(45.7) 
16 
(25.8*) 
12 
(24.5*) 
7 (31.8) 
Neurologic 
disorder 
230 
(21.3) 
 
51 
(16.6) 
69 
(24.5*) 
90 
(26.2*) 
11 (9.9) 43 
(18.5) 
15 
(16.3) 
15 
(24.2) 
11 
(22.4) 
1 (4.5) 
Discoid rash 179 
(16.6) 
 
27 (8.8)  73 
(25.9*) 
58 
(16.9*) 
17 
(15.3) 
32 
(13.8) 
9 (9.8) 16 
(25.8*) 
5 (10.2) 1 (4.5) 
ACR case definition: meets ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE.  
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-Hispanic black, 
non-Hispanic Asian, Hispanic, and non-Hispanic other. Non-Hispanic cases identified with more than one race were 
categorized as non-Hispanic other.  
* Univariate logistic regression indicates the proportion with this manifestation is significantly different than the proportion 
among non-Hispanic whites (p<0.05).            
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Table 3: Crude and age-standardized incidence rates of SLE among Manhattan residents, 2007-2009, according to the ACR, 
SLICC, and rheumatologist case definitions overall and by race/ethnicity and sex  
 ACR  SLICC Rheumatologist 
N Crude 
rate 
(95% 
CI) 
Age-
standardized 
rate (95% 
CI) 
Capture-recapture  N Crude 
rate 
(95% 
CI) 
Age-
standardized 
rate (95% 
CI) 
N Crude 
rate 
(95% 
CI) 
Age-
standardized 
rate (95% 
CI) 
N missed Adjusted 
rate (95% 
CI) 
Overall 232 4.9 
(4.3-
5.5) 
4.6 (4.0-5.2) 284.4 6.0 (4.6-
7.4) 
312 6.6 
(5.8-
7.3) 
6.2 (5.5-6.9) 253 5.3 
(4.7-
6.0) 
5.0 (4.4-5.7) 
Male 23 1.0 
(0.7-
1.5) 
1.0 (0.6-1.5) 26.3 1.2 (0.7-
1.7) 
38 1.7 
(1.2-
2.3) 
1.7 (1.2-2.3) 28 1.3 
(0.8-
1.8) 
1.2 (0.8-1.8) 
Female 209 8.3 
(7.2-
9.4) 
7.9 (6.8-9.0) 258.1 10.3 (8.0-
12.5) 
274 10.9 
(9.6-
12.2) 
10.3 (9.1-
11.6) 
225 8.9 
(7.8-
10.1) 
8.6 (7.4-9.7) 
Non-
Hispanic 
White 
92 4.0 
(3.2-
4.9) 
3.6 (2.8-4.5) 128.7 5.6 (4.2-
7.1) 
124 5.4 
(4.5-
6.4) 
4.8 (3.9-5.8) 94 4.1 
(3.3-
5.0) 
3.8 (3.0-4.8) 
Male 7 0.6 
(0.3-
1.3) 
0.5 (0.2-1.0) 8.6 0.8 (0.4-
1.2) 
13 1.2 
(0.6-
2.0) 
1.0 (0.5-1.7) 9 0.8 
(0.4-
1.6) 
0.7 (0.3-1.3) 
Female 85 7.1 
(5.7-
8.8) 
6.5 (5.0-8.3) 120.1 10.1 (7.7-
12.5) 
111 9.3 
(7.6-
11.1) 
8.5 (6.7-
10.3) 
85 7.1 
(5.7-
8.8) 
6.8 (5.2-8.6) 
Non-
Hispanic 
Black 
62 9.8 
(7.5-
12.6) 
9.3 (7.1-
12.0) 
63.8 10.1 (9.1-
11.0) 
79 12.5 
(9.9-
15.5) 
12.0 (9.5-
15.0) 
61 9.6 
(7.4-
12.4) 
9.2 (7.0-
11.8) 
Male 7 2.4 
(1.0-
5.0) 
2.4 (1.0-5.0) 8.0 2.8 (1.6-
3.9) 
11 3.8 
(1.9-
6.8) 
3.8 (1.9-6.8) 7 2.4 
(1.0-
5.0) 
2.3 (0.9-4.7) 
Female 55 16.0 
(12.1-
20.9) 
15.7 (11.8-
20.5) 
55.8 16.3 (15.5-
17.0) 
68 19.8 
(15.4-
25.1) 
19.3 (14.9-
24.5) 
54 15.7 
(11.8-
20.5) 
15.5 (11.6-
20.3) 
Hispanic 49 4.0 
(3.0-
5.3) 
4.0 (3.0-5.4) 50.3 4.1 (3.8-
4.5) 
64 5.2 
(4.0-
6.7) 
5.3 (4.1-6.7) 50 4.1 
(3.0-
5.4) 
4.2 (3.1-5.5) 
Male 7 1.2 
(0.5-
2.5) 
1.3 (0.5-2.7) 7.4 1.3 (1.0-
1.5) 
8 1.4 
(0.6-
2.7) 
1.6 (0.7-3.2) 6 1.0 
(0.4-
2.3) 
1.1 (0.4-2.5) 
Female 42 6.5 
(4.7-
8.8) 
6.5 (4.7-8.8) 42.9 6.7 (6.2-
7.1) 
56 8.7 
(6.6-
11.3) 
8.6 (6.5-
11.2) 
44 6.8 
(5.0-
9.2) 
7.0 (5.1-9.4) 
Non-
Hispanic 
Asian 
22 4.2 
(2.6-
6.3) 
3.8 (2.3-6.0) 28.7 5.4 (3.3-
7.5) 
31 5.8 
(4.0-
8.3) 
5.3 (3.4-7.7) 27 5.1 
(3.4-
7.4) 
4.5 (2.9-6.9) 
Male 1 0.4 
(0.0-
2.4) 
0.5 (0.0-2.7) 1.3 0.6 (0.0-
1.1) 
2 0.8 
(0.1-
3.1) 
1.0 (0.1-3.5) 2 0.8 
(0.1-
3.1) 
1.0 (0.1-3.7) 
Female 21 7.1 
(4.4-
10.9) 
6.6 (3.8-
10.5) 
27.4 9.3 (6.0-
12.7) 
29 9.9 
(6.6-
14.2) 
8.8 (5.6-
13.1) 
25 8.5 
(5.5-
12.6) 
7.5 (4.5-
11.6) 
Non-
Hispanic 
Other 
7   12.9  14   21   
Case definitions: ACR: meet ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE; SLICC: have 
sufficient criteria to meet the Systemic Lupus Erythematosus Collaborating Clinics (SLICC) classification; Rheumatologist: have 
been diagnosed with SLE by a treating rheumatologist    
Rates are per 100,000 Manhattan resident person-years. Denominator data is based on 2007-2009 intercensal population 
estimates from the NYC DOHMH Bureau of Epi Services (2000-2014 files). Data are standardized for age and race/ethnicity  to 
the US 2000 Standard Population.Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic 
white, non-Hispanic black, non-Hispanic Asian, Hispanic, and non-Hispanic other. Non-Hispanic cases identified with more than 
one race were categorized as non-Hispanic other.   
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Table 4: Unique manifestations among SLE incident and prevalent cases meeting SLICC but not ACR case definitions 
 N % 
Overall  310  
Immunologic criteria   
    Low complements 151 48.7% 
    Anti-Beta2 Glycoprotein Antibodies (IgG, or IgM) 16 5.2% 
    Direct Coombs test in the absence of hemolytic anemia 5 1.6% 
   
Clinical criteria   
Acute cutaneous lupus   
    Bullous lupus 1 0.3% 
    Toxic epidermal necrolysis variant of SLE  0 0.0% 
    Maculopapular lupus rash  13 4.2% 
    Subacute cutaneous lupus  4 1.3% 
Chronic cutaneous lupus   
    Hypertrophic (verrucous) lupus 3 1.0% 
    Lupus Panniculitis (profundus) 4 1.3% 
    Mucosal lupus  0 0.0% 
    Lupus erythematosus tumidus 1 0.3% 
    Chilblains lupus 1 0.3% 
    Discoid lupus/Lichen planus overlap 4 1.3% 
Non-scarring alopecia 122 39.4% 
Neurologic criteria   
    Mononeuritis multiplex 3 1.0% 
    Myelitis 2 0.6% 
    Peripheral or cranial neuropathy 53 17.1% 
    Acute confusional state 3 1.0% 
Lymphopenia 147 47.4% 
 
Antinuclear antibody or anti-double stranded DNA and biopsy proven 
lupus nephritis and renal biopsy only 
17 5.5% 
SLICC: Systemic Lupus Erythematosus Collaborating Clinics  
ACR: American College of Rheumatology 
Criteria are not mutually exclusive; a case may have more than one criteria listed above.    
Data on IgA isotypes for anti–B2glycoprotein I and anti-cardiolipin antibodies were not collected. Anti-dsDNA when done 
by ELISA was only reported as positive or negative so it is possible that is some cases this criterion was over counted in 
the SLICC if the positive was not specifically double the upper cutoff for the negative value. Finally, CH50 was not 
captured and thus it is possible that the SLICC criterion for complement could be under-counted. 
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Figure 1. Flow chart showing the Manhattan Lupus Surveillance Program case-
finding procedure for Systemic Lupus Erythematosus  
 
ACR case definition: meet ≥ 4 of 11 American College of Rheumatology (ACR) 
classification criteria for SLE 
SLICC case definition: have sufficient criteria to meet the Systemic Lupus 
Erythematosus Collaborating Clinics (SLICC) classification 
Rheumatologist definition: have been diagnosed with SLE by a treating rheumatologist 
 
  
Figure 2. Age-specific prevalence and incidence rates of SLE among Manhattan 
residents in 2007 and from 2007-2009 by ACR case definition, by age group 
among females 
 
ACR case definition: meets ≥ 4 of 11 American College of Rheumatology (ACR) 
classification criteria for SLE 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-
Hispanic white, non-Hispanic black, non-Hispanic Asian, Hispanic, and non-Hispanic 
other.  
Non-Hispanic cases identified with more than one race were categorized as non-
Hispanic other and are not shown in this figure. 
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Figure 2. Age-specific prevalence and incidence rates of SLE among Manhattan residents in 2007 and from 
2007-2009 by ACR case definition, by age group among females  
 
ACR case definition: meets ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-
Hispanic black, non-Hispanic Asian, Hispanic, and non-Hispanic other.  
Non-Hispanic cases identified with more than one race were categorized as non-Hispanic other and are not 
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Abstract  
Objective: The Manhattan Lupus Surveillance Program (MLSP) is a population-based 
registry designed to determine the prevalence of Systemic Lupus Erythematosus (SLE) 
in 2007 and incidence from 2007 to 2009 among Manhattan residents and characterize 
cases by race/ethnicity, including Asians and Hispanics for whom data are lacking. 
Methods: We identified possible SLE cases from hospitals, rheumatologists, and 
administrative databases and defined cases using the American College of 
Rheumatology (ACR) classification criteria, the Systemic Lupus International 
Collaborating Clinics (SLICC) classification criteria, or a treating rheumatologist’s 
diagnosis. Rates among Manhattan residents were age-adjustedstandardized, and 
capture-recapture (C-RC) analyses were conducted to assess case under-
ascertainment.   
Results: By the ACR definition, the age-adjusted standardized prevalence and 
incidence rates of SLE were 62.2 and 4.6 per 100,000 person-years. Rates were 
approximately nine times higher in women than men for prevalence (107.4 vs. 12.5) and 
incidence (7.9 vs. 1.0). Compared with non-Hispanic (NH) white women (64.3), 
prevalence rates were was higher among NH-black (210.9), Hispanic (138.3), and NH-
Asian women (91.2). Incidence rates were higher among NH-black women (15.7) 
compared with NH-Asian (6.6), Hispanic (6.5), and NH-white women (6.5). C-RC 
adjustment increased prevalence and incidence rates (75.9 and 6.0). Alternate SLE 
definitions without C-RC adjustment found higher age-adjusted standardized prevalence 
and incidence rates (SLICC: 73.8 and 6.2; rheumatologist: 72.6 and 5.0) than the ACR 
definition, with similar patterns by sex and race/ethnicity.   
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Conclusion: The MLSP confirms findings from other registries on disparities by sex 
and race/ethnicity, provides new estimates among Asians and Hispanics, and also 
provides estimates using the SLICC criteria.  
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Introduction: 
 Systemic Lupus Erythematosus (SLE) is a potentially fatal, heterogeneous, chronic, 
systemic autoimmune disease of unknown etiology [1]. Given widely varying estimates 
of the incidence and prevalence of SLE in the United States (US) [2] and the absence of 
data available for certain demographic groups, we sought to obtain a fundamental 
epidemiologic understanding of SLE across racial/ethnic groups. Under the auspices of 
the National Arthritis Action Plan [3], the Centers for Disease Control and Prevention 
(CDC) funded four state or city health departments as well as the Indian Health Service 
(IHS) to more robustly define the incidence and prevalence of SLE. Results from the 
two initial sites, the Georgia Lupus Registry (GLR) and the Michigan Lupus 
Epidemiology and Surveillance Program (MILES Program), and the IHS site have been 
recently published [4-6]. However, their estimates for Asians and Hispanics were 
limited. The Manhattan Lupus Surveillance Program (MLSP) was designed, along with 
the California Lupus Surveillance Project (CLSP), to provide estimates of the incidence 
and prevalence of SLE overall and specifically among Hispanic and Asian populations.  
 We launched the MLSP in 2009 as a collaboration between the New York City 
Department of Health and Mental Hygiene (DOHMH) and New York University School 
of Medicine (NYUSoM). Following methods similar to those of the other CDC-funded 
sites [2, 5, 6], we designed the MLSP as a retrospective descriptive project to identify all 
cases of diagnosed SLE among Manhattan residents from 2007 to 2009 to determine 
the prevalence and incidence of SLE in this population. 
Patients and Methods 
The Manhattan Lupus Surveillance Program 
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 The MLSP was designed to be similar to the GLR and MILES program and, as 
described elsewhere [5, 6], was conducted as a public health surveillance project by the 
DOHMH with NYUSoM acting as a public health agent on behalf of the DOHMH. No 
patients were contacted for this project. Medical records were collected under the health 
surveillance exemption to the Health Insurance Portability and Accountability Act 
(HIPAA) privacy rules (45 CFR § 164.512(b)) and as authorized by New York City 
Charter Sections 556(c)(2) and (d)(2). The CDC deemed the MLSP public health 
practice not requiring review by the CDC Institutional Review Board (IRB). IRBs at both 
the DOHMH and NYUSoM reviewed and deemed the MLSP a surveillance activity. 
Additional IRB applications were completed and submitted to independent case finding 
sources as requested.  
Study Population and Period 
 The MLSP surveillance period was January 1, 2007, through December 31, 2009. 
Manhattan was selected as the program catchment area due to its racial/ethnic diversity 
and because it is an island on which inhabitants largely remain for their health care, 
thus making access to medical records easier. We used data from specialty lupus 
clinics across NYC during initial planning for the MLSP and found that few Manhattan 
residents seek care in outer boroughs and that residents from other boroughs were 
more likely to seek care across a wide geographic range. Based on United States 
Census data, there were 1,611,581 persons residing in Manhattan in 2010 (48% non-
Hispanic (NH) white, 13% NH-black, 25% Hispanic, 11% NH-Asian) [7].  
Case Definitions 
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Our primary American College of Rheumatology (ACR) case definition required > 
4 of 11 ACR classification criteria for SLE [8, 9]. Under the ACR classification criteria, 
patients with evidence of lupus nephritis (by biopsy report or specific documentation by 
a rheumatologist and/or nephrologist) are considered to have met renal criteria for SLE, 
even without information on the degree of proteinuria or description of the sediment. We 
also used two secondary case definitions for SLE: 1) the Systemic Lupus 
Erythematosus Collaborating Clinics (SLICC) classification criteria, which requires a 
case to have at least four criteria, including at least one clinical and one immunologic 
criterion or having biopsy-proven lupus nephritis in the presence of antinuclear 
antibodies or anti-double-stranded DNA antibodies, or 2) a treating rheumatologist’s 
diagnosis of SLE. The SLICC case definition was included as a recently derived 
classification criteria with greater sensitivity and less specificity than the ACR 
classification criteria [10]. The rheumatologist case definition was included because 
there is no gold standard for diagnosing SLE and diagnosis is usually made by a 
physician familiar with the disease, often a rheumatologist. 
Initial Case Finding  
 
We used information from administrative databases, hospitals, and private 
rheumatologists to identify possible cases from as far back as 2004 when records were 
available. Administrative databases included the New York State Department of Health 
Statewide Planning and Research Cooperative System with information on 
hospitalization discharges in New York State and DOHMH Vital Records with 
information on all deaths in NYC. We included only hospitals and private 
rheumatologists based in Manhattan. We queried these sources to identify records with 
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International Classification of Disease (Ninth Revision, Clinical Modification) diagnosis 
codes indicating SLE (710.0), discoid lupus (695.4), or a related condition that may 
evolve into SLE or have related symptoms (710.8, other specified connective tissue 
disease; 710.9, unspecified connective tissue disease; 710.2, Sicca syndrome). If 
residence information was available from the case finding source, we further restricted 
these records to include only those with evidence of Manhattan residence. Final 
screening of records was completed by trained MLSP abstractors to confirm physician 
diagnosis or suspicion of SLE or a related connective tissue disease and Manhattan 
residence during the surveillance period.  
Data collection 
After initial case finding, abstractors collected and entered information from the 
medical records into a DOHMH database, with database and data dictionary materials 
adapted from those used by the GLR. When necessary, we corroborated Manhattan 
residence using the LexisNexis on-line database service [11]. Our abstractors entered 
any ambiguous information into open text notes which were later reviewed with the 
NYUSoM principal investigator to correctly code in the database.  
All MLSP abstractors were trained under the GLR model [5] before abstraction 
began and underwent routine quality assurance reviews throughout the project. These 
reviews provided the opportunity for abstractors and the NYUSoM principal investigator 
to discuss any issues arising in the field and to address questions from the abstractors. 
Each abstractor had a medical degree and consistently achieved the required minimum 
inter-observer agreement of 90% on all elements and 95% on ACR classification criteria 
using abstraction by the NYUSoM principal investigator as the gold standard. The 
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average performance of the abstractors during training and reviews was 95.6% on all 
elements,  and 97.2% on ACR classification criteria elements, and 97.5% on the unique 
elements in the SLICC classification criteria that were not already captured as part of 
the ACR classification criteria.  
Statistical Analysis 
We defined prevalent cases  as new or existing cases meeting the ACR, SLICC, 
or rheumatologist case definition and residing in Manhattan at some time from January 
1, 2007, through December 31, 2007. We defined incident cases as those meeting at 
least one of the case definitions, first diagnosed from January 1, 2007, through 
December 31, 2009, and residing in Manhattan. Population denominators were taken 
from the DOHMH interpolated intercensal population estimates for Manhattan [12]. We 
calculated rates overall, by sex, and by race/ethnicity per 100,000 person-years and 
age-adjusted standardized to the United States 2000 standard population using 10 year 
age groups for each racial/ethnic group [13]. Information on race was collected 
separately from Hispanic ethnicity during abstraction. For analysis, we assigned cases 
to one of five mutually exclusive race/ethnicity categories: NH-white, NH-black, NH-
Asian, Hispanic, and NH-other. NH-cases identified with more than one race were 
categorized as other.   
We conducted capture-recapture (C-RC) analyses [14, 15] to estimate case 
under-ascertainment from our primary ACR case definition. We fit log-linear models 
separately for incident and prevalent cases by sex and race/ethnicity to estimate the 
number of cases missed in our catchment area. Specifically, we fit various models that 
addressed potential violation of the homogeneity assumption of capture probability and 
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identified the best fitting model using the Akaike Information Criteria. We then used 
estimates from these models to calculate revised prevalence and incidence and 
prevalence rates. 
 We used chi-square tests, or Fisher’s exact tests when needed, to assess 
univariate differences in SLE and ACR manifestations by race/ethnicity and sex. We 
compared differences between estimates by case definition using 95% confidence 
intervals (CIs) of the age-adjusted standardized rates, with non-overlapping CIs 
considered to be significantly different. All analyses were completed using SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA) and R version 3.3.0 (R Foundation for Statistical 
Computing, Vienna, Austria). 
Results: 
 
Case Finding 
 
Case finding and abstraction was completed in 19 out of 21 hospitals (90.5%, 
Figure 1), with two hospitals declining to participate (a cancer specialty hospital, and a 
Veteran’s Administration Hospital). Case finding and abstraction was performed from 
records of 94 out of 124 (75.8%) private rheumatologists identified in the catchment 
area. Of the 30 rheumatologists who did not participate, 19 did not respond to repeated 
requests or declined to participate, two died, two had retired and relocated, and seven 
agreed to participate but abstraction could not be arranged despite repeated attempts 
before data abstraction ended.  
Initial lists provided from the various case finding sources identified 76,220 
records (Figure 1). We deduplicated and removed records that did not have a 
Manhattan address, resulting in 5,065 possible cases with records for abstraction. 
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During abstraction and data cleaning, we deemed 1,184 cases ineligible due to 
miscoded diagnosis or non-Manhattan residence. Of the remaining 3,881 possible 
cases, 1,859 met at least one of the case definitions.    
Primary ACR Case Definition: Prevalence Rates 
 
In 2007 a total of 1,078 cases (307 NH-white, 282 NH-black, 344 Hispanic, 111 
NH-Asian, and 34 NH-other race/ethnicity) fulfilled the ACR case definition for SLE 
(Table 1). The overall crude and age-adjusted standardized prevalence rates were was 
68.2 (95% CI 64.1-72.2) and 62.2 (95% CI 58.4-66.0) per 100,000 person-years. Age-
adjusted standardized rates were approximately nine times higher for women compared 
with men (107.4 vs. 12.5). Age-adjusted standardized rates also differed by 
race/ethnicity among both women and men. The highest age-adjusted standardized 
prevalence rates were was seen among NH-black women (210.9) followed by Hispanic 
women (138.3), NH-Asian women (91.2), and NH-white women (64.3). The age-
adjusted standardized prevalence rates among men followed a similar pattern with the 
highest rate estimate among NH-blacks (26.7) followed by Hispanics (19.4), NH-Asians 
(14.2), and NH-whites (3.7). C-RC estimated an additional 122 cases of SLE, indicating 
that 10% of cases may have been missed. Almost two-thirds (62.5%) of the estimated 
cases missed were NH-white women. With C-RC adjustment, the prevalence rate 
increased to 75.9 per 100,000 person-years (95% CI 70.6-81.2).  
The average age (± standard deviation [SD]) among women and men with SLE 
living in Manhattan in 2007 was 43.3 (± 15.5) and 40.7 (± 16.9) years respectively. The 
average age by race/ethnicity was 47.0 (± 16.5) years among NH-whites, 42.9 (± 15.6) 
years among Hispanics, 41.5 (± 13.7) years among NH-blacks, and 37.3 (± 15.4) years 
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among NH-Asians. Figures 2A shows age-specific prevalence rates for women by 
race/ethnicity. Prevalence rates were was higher among NH-black and Hispanic women 
ages 20 to 59 years old compared to similarly-aged NH-white women. Prevalence rates 
among NH-Asian women were was not significantly different than those among NH-
white women for any age group. Numbers among men were too small to assess age-
specific rates by race/ethnicity. 
  Among the 344 Hispanic cases, 82.9% were also identified as white, 11.3% as 
black, and 5.8% as other race/ethnicity. Information on Hispanic ethnicity was often 
absent, with 239 (69.5%) having no further details, but Hispanic case ethnicities 
included Central or South American, Cuban, Dominican, Mexican, Puerto Rican, and 
Spanish. There were 111 NH-Asian cases as well as five identified as NH-other due to 
multiple race/ethnicity but with evidence of Asian race. More than a quarter (26.7%) of 
these cases had no further classification for Asian ethnicity, but ethnicities among cases 
with information available included Chinese, Filipino, Hawaiian, Indian or Pakistani, 
Japanese, Korean, Pacific Islander not otherwise specified, South Asian, and 
Vietnamese.   
 Table 2 shows the occurrence of the 11 ACR criteria overall and by race/ethnicity 
among prevalent ACR cases. Renal disease was more common among NH-Asians 
(53.2%), NH-blacks (50.7%), and Hispanics (49.4%) compared with NH-whites (25.4%). 
Neurologic manifestations were more common among Hispanics (26.2%) and NH-
blacks (24.5%) compared with NH-whites (16.6%). Also compared with NH-whites, 
discoid lesions were more commonly seen among NH-blacks (25.9% vs. 8.8%) and 
malar rash was more commonly seen among Hispanics (50.0% vs. 35.8%).  
Page 42 of 60
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
13 
 
Primary ACR Case Definition: Incidence Rates 
 
From 2007-2009, 232 incident cases met the ACR case definition (Table 3) for 
SLE (92 NH-white, 62 NH-black, 49 Hispanic, 22 NH-Asian, and 7 NH-other 
race/ethnicity). The overall crude and age-adjusted standardized incidence rates were 
4.9 (95% CI 4.3-5.5) and 4.6 (95% CI 4.0-5.2) per 100,000 person-years respectively. 
Age-adjusted standardized rates differed by sex, and were almost 8 times higher for 
women compared with men (7.9 vs. 1.0). Age-adjusted standardized rates also differed 
by race/ethnicity among both women and men. The highest age-adjusted standardized 
incidence rates among women were among NH-blacks (15.7) followed by NH-Asians 
(6.6), Hispanics (6.5), and NH-whites (6.5). Similarly, the highest age-adjusted 
standardized incidence rates among men were among NH-blacks (2.4) followed by 
Hispanics (1.3), NH-Asians (0.5), and NH-whites (0.5). C-RC adjustment estimated 284 
incident cases of SLE, indicating that 18% of cases were missed and 67.0% of these 
were NH-white women. The resulting C-RC adjusted incidence rate increased to 6.0 per 
100,000 person-years (95% CI 4.6-7.4).  
The average age (±SD) at diagnosis was 40.4 (± 16.6) years among women and 
42.9 (± 20.4) years among men. The average age (±SD) at diagnosis was 42.2 (± 17.7) 
years among NH-whites, 39.2 (± 16.6) years among NH-blacks, 39.6 (± 17.0) years 
among Hispanics, and 37.9 (± 16.0) years among NH-Asians. Figure 2B shows age-
specific incidence rates for women by race/ethnicity. The only age-specific difference 
was between NH-black and NH-white women aged 20 to 39 years old. Otherwise, due 
to small numbers within each strata, no age-specific differences were found. 
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  Among the 49 incident Hispanic cases, 77.6% were also identified as NH-white, 
16.3% as NH-black, and 6.1% as NH-other race/ethnicity. As with prevalent cases, 
Hispanic ethnicity information for incident cases was often absent, with 71.4% having no 
further ethnicity information available.  Among the 22 incident NH-Asian cases, 32% 
had no further data available.  
Table 2 shows the occurrence of the 11 ACR criteria overall and by race/ethnicity 
among incident ACR cases. Evidence of renal disease was found among 34.9% of 
incident cases, but was more common among NH-Asians (45.5%), NH-blacks (43.5%), 
and Hispanics (42.9%) compared with NH-whites (23.9%). Discoid lesions were more 
common among NH-blacks (25.8%) compared with NH-whites (9.8%). 
Secondary Case Definitions 
 Prevalence and incidence rates calculated using the SLICC case definition for 
SLE were significantly higher than those calculated with the primary case ACR 
definition. Using the SLICC case definition generated crude and age-adjusted 
standardized prevalence rates of 80.1 (95% CI 75.7-84.5) and 73.8 (95% CI 69.6-77.9) 
per 100,000 years respectively, which were 17-19% higher than those calculated with 
the ACR case definition. The SLICC crude and age-adjusted standardized incidence 
rates (6.6, 95% CI 5.8-7.3; 6.2, 95% CI 5.5-6.9) were nearly 35% higher than the ACR 
incidence rates.  
The rheumatologist case definition yielded crude and age-adjusted standardized 
prevalence rates that were was approximately 17% higher than those from the ACR 
case definition (79.4, 95% CI 75.0-83.8; 72.6, 95% CI 68.5-76.7). Crude and age-
adjusted standardized incidence rates using the rheumatologist case definition were 
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similar to rates using the ACR case definition (5.3, 95% CI 4.7-6.0; 5.0, 95% CI 4.4-5.7). 
For both secondary case definitions differences in rates by sex and race/ethnicity were 
similar to those identified by the ACR case definition.  
 Of the 1,538 incident and prevalent cases meeting either the ACR or SLICC case 
definition, 75.6% met both ACR and SLICC definitions, 4.3% only met the ACR 
definition, and 20.2% met the SLICC definition only. Table 4 displays information on the 
unique SLICC criteria that are not part of the ACR classification criteria among incident 
and prevalent cases meeting the SLICC case definition only. The most common unique 
SLICC criteria among these cases were low complement levels, alopecia, and different 
definitions for lymphopenia. In addition, 5.5% of cases meeting the SLICC case 
definition had an ANA and/or anti–double-stranded DNA antibody and a biopsy 
consistent with lupus nephritis. Reasons that cases met the ACR and not the SLICC 
case definition were largely due to having > 4 clinical criteria but no immunologic 
criteria, differences in categorization of photosensitivity and malar rash (which were 
separated in the ACR and combined in the SLICC criteria), and differences in defining 
lymphopenia and anti-cardiolipin antibody (data not shown).    
Discussion 
Our analysis of the MLSP provides prevalence and incidence rate estimates of 
SLE among Manhattan residents using methods similar to other CDC-funded SLE 
registries. Our analysis confirms evidence for higher prevalence of SLE among NH-
blacks compared with NH-whites and adds evidence for higher prevalence of SLE 
among Hispanics and NH-Asians as well. The MLSP is also the first among the CDC-
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funded SLE registry sites to report using the SLICC classification criteria, which were 
recently validated, to describe cases of SLE [10]. 
Based on case finding and data abstraction from administrative databases, 
hospitals, and private rheumatology practices, we identified 1,078 prevalent cases of 
SLE in Manhattan in 2007 and 232 incident cases from 2007-2009, The resulting in 
age-adjusted standardized prevalence and incidence rates of SLE in Manhattan were 
62.2 (95% CI 58.4-66.0) and 4.6 (95% CI 4.0-5.2) using the ACR case definition. 
Compared with previous reports by the CDC-funded sites , we estimated slightly lower 
overall age-adjusted standardized prevalence rates than the GLR (73.0, 95% CI 68.9-
77.4) [5] and MILES (72.8, 95% CI 70.8-74.8) [6], but found similar disparities by sex 
and race/ethnicity for NH-whites and NH-blacks. MLSP prevalence estimates increased 
with C-RC adjustment and were comparable to C-RC adjusted estimates from the GLR 
(75.8, 95% CI 70.3-81.2 vs. 83.0, 95% CI 78.6-87.7).  Our age-adjusted standardized 
incidence rates using the ACR case definition were similar to those from the GLR and 
MILES. 
We found the highest prevalence and incidence rates among NH-blacks, in line 
with the GLR and MILES and with preliminary data from the CLSP. However, unlike the 
GLR and MILES we found elevated prevalence rates among NH-Asians and Hispanics 
compared with NH-whites. Compared with preliminary crude estimates from the CLSP 
[16] the MLSP showed similar elevated rates among Hispanics (84.2, 95% CI 75.3-93.1 
vs 87.7 95% CI 72.1-106.8) and  but slightly lower rates among NH-Asians (64.0, 95% 
CI 52.1-75.9 vs 95.8 95% CI 84.9-108.1). These MLSP findings are particularly 
important, given the few published studies on prevalence and incidence of SLE among 
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Asians and Hispanics in the United States. A 1973 review presented estimates among 
NYC residents from 1956 to 1965 but focused only on whites, blacks, and Puerto 
Ricans [17]. Another study published in 2001 estimated the prevalence of SLE among 
Hispanics in Arizona to be 103 per 100,000, slightly higher than the rate found by the 
MLSP among Hispanics in Manhattan [18]. A more recent study using Medicaid data 
estimated an even higher prevalence rate of SLE among Hispanics (126.5 per 100,000) 
with Medicaid coverage in the United States from 2000 to 2004 [19].  
The study using Medicaid data is one of the few to estimate rates of SLE among 
Asians in the United States, reporting a prevalence rate almost four times that estimated 
by the MLSP (175.1 per 100,000 vs. 45.7) [19]. The only other studies known to assess 
rates SLE among Asians in the United States focused on SLE prevalence. One study 
identified cases in Hawaii based on physician diagnosis at five medical centers and 
outpatient practices in 1989. The overall SLE prevalence rate identified in that study 
(41.8 per 100,000) was similar to the MLSP estimate for NH-Asians, and the age-
adjusted standardized rates for women from specific Asian ethnic groups (Chinese, 
Filipino, Hawaiian, Japanese) was found to be higher compared with that among white 
women [20]. Another study, using hospital discharge data, reported that Asian/Pacific 
Islander women had a lower rate of prevalent SLE compared with white women [21]. 
Less is known about the incidence of SLE among Asians. In England, new diagnoses of 
SLE are more common among Asians, specifically South Asians from India and 
Pakistan, compared with whites [22, 23], but to our knowledge there are no other 
published reports on the incidence of SLE among Asians in the United States.   
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In this analysis, we also provide information on manifestations among SLE 
cases. Clinical or serologic manifestations among prevalent cases approximated those 
from the GLR and MILES registries. The MLSP found a high burden of nephritis overall 
with nearly half (42.4%) of prevalent cases developing nephritis. The proportion of those 
with nephritis was higher among non-white prevalent cases, specifically 50.7% among 
NH-blacks, 49.4% among Hispanics, and 53.2% among NH-Asians, compared with 
25.4% among NH-whites, in line with other studies [5, 6, 19, 24, 25].    
The SLICC case definition for SLE yielded higher incidence and prevalence 
estimates than the ACR case definition. Unique criteria which substantiated the 
classification of SLE based on SLICC but not ACR criteria, included low complements, 
alopecia, and different definitions for lymphopenia [10]. The small number of cases that 
met the ACR but not the SLICC case definition is reassuring as it suggests that few 
cases met ACR criteria for SLE without the presence of autoantibodies. However, given 
the descriptive nature of the MLSP and the absence of a gold standard test that would 
unambiguously identify SLE, this project cannot assess which set of classification 
criteria is more sensitive or specific. In addition, non-overlapping confidence intervals 
were used to conservatively assess differences among rates (26).  
There were several limitations to this project. First, we may have underestimated 
cases as two hospitals and one quarter of rheumatologists in the catchment area 
declined to participate. Most of the practices that did not participate were in 
neighborhoods with a majority white population, which is in line with our C-RC analysis 
that estimated 67.3% of prevalent cases and 70.0% of incident cases missed were NH-
white. However, the exclusion of the Veteran’s Administration Hospital may have 
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resulted in under-identification of males diagnosed with SLE. We also did not include 
nephrology, dermatology, or primary or alternative care practices among our case 
finding sources. Though when possible we did query hospital pathology databases for 
relevant kidney or skin biopsies, we still may have missed milder cases that were not 
hospitalized or seen by a rheumatologist during the surveillance period. It is also 
possible that we missed cases if they lived in Manhattan but sought care in other 
boroughs or a neighboring state. 
Second, medical systems differed tremendously, and any difficulty navigating 
different electronic medical records or with the legibility of paper charts could have led 
to missed or miscoded data. Additionally, medical records are designed for physician 
use, not for data abstraction and surveillance. Thus, some information of interest may 
have been missing or ambiguous, depending on what was collected and recorded by 
the case finding source.  
Third, abstracting occurred several years after the surveillance period, which 
could have led to missing information if records were put into storage or data elements 
were lost during a facility’s migration from paper to electronic records. This lag time may 
have also affected our ability to find all prevalent cases of SLE, as some newer systems 
were unable to query past certain dates. Additionally, many private practices did not 
retain information on patients’ prior addresses, so we may not have abstracted cases 
who moved outside of Manhattan since the surveillance period. However, when 
possible the software LexisNexis was used to verify patient residence within the 
catchment area.  
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Finally, data on race and ethnicity was abstracted from administrative and 
medical records, which may not accurately represent the patient’s own racial or ethnic 
identification. Additionally, information on ethnicity was often missing or did not include 
detail such as country of origin, which limited our ability to describe rates of SLE among 
specific ethnic groups. Though available information did reflect the major ethnic groups 
in Manhattan, ethnicity information was missing for most Hispanic cases and more than 
one quarter of NH-Asian cases. Categorized broadly, Hispanic or Asian race 
encompasses a number of heterogeneous groups and SLE rates among them may 
differ. Given the already limited number of published studies on SLE among Asians and 
Hispanics, additional work is needed to better describe and understand the experience 
of SLE among specific ethnic subpopulations.  
Despite these limitations, our analysis benefitted from the design and 
composition of the MLSP. First, the MLSP was designed as a population-based registry 
with methods similar to four other CDC-funded SLE registries, which allowed us to 
compare rates across sites. Second, the diverse population within our catchment area 
allowed us to estimate rates of SLE among the major racial categories, particularly 
Asians and Hispanics. Third, given the recent publication of the SLICC classification 
criteria, we were able to estimate rates of SLE by this case definition and compare them 
to the ACR case definition. Fourth, the partnership with the DOHMH allowed us to 
collect information from a number of case finding sources and find complete clinical 
information on most cases. Finally, our abstractors all had a medical background, which 
helped during training and also provided an advantage during extensive review of 
medical records to identify SLE criteria. 
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In conclusion, we found substantial disparities in prevalence, incidence, and 
manifestations of SLE by sex and race/ethnicity among Manhattan residents. Women 
consistently had higher prevalence and incidence rates of SLE compared with men, and 
NH-blacks, Hispanics, and NH-Asians had higher rates of diagnosed SLE and a higher 
proportion lupus nephritis compared with NH-whites. The highest rates of SLE were 
seen among NH-black women followed by Hispanic, NH-Asian, and NH-white women. 
Using the SLICC criteria for SLE provided higher prevalence and incidence rates than 
the ACR criteria. 
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Table 1: Crude and age-adjusted standardized prevalence rates of SLE among Manhattan residents, 2007, according to the ACR, SLICC, and 
rheumatologist case definitions overall and by race/ethnicity and sex 
 ACR  SLICC Rheumatologist 
N Crude 
rate 
(95% CI) 
Age-adjusted 
standardized 
rate (95% CI) 
Capture-recapture  N Crude 
rate 
(95% CI) 
Age-adjusted 
standardized 
rate (95% CI) 
N Crude 
rate 
(95% CI) 
Age-adjusted 
standardized 
rate (95% CI) 
N 
missed 
Adjusted 
rate 
(95% CI) 
Overall 1,078 68.2 
(64.1-
72.2) 
62.2 (58.4-66.0) 122.4 75.9 
(70.6-
81.2) 
1,267 80.1 
(75.7-
84.5) 
73.8 (69.6-77.9) 1,256 79.4 
(75.0-
83.8) 
72.6 (68.5-76.7) 
Male 101 13.6 
(10.9-
16.2) 
12.5 (10.0-15.0) 8.3 14.7 
(12.5-
16.9) 
110 14.8 
(12.0-
17.6) 
13.8 (11.1-16.4) 98 13.2 
(10.7-
16.1) 
12.0 (9.7-14.7) 
Female 977 116.7 
(109.3-
124.0) 
107.4 (100.5-
114.4) 
114.1 130.3 
(122.1-
138.4) 
1,157 138.2 
(130.2-
146.1) 
128.3 (120.7-
135.9) 
1,158 138.3 
(130.3-
146.2) 
127.5 (119.9-
135.1) 
Non-
Hispanic 
White 
307 40.5 
(36.0-
45.0) 
34.7 (30.7-38.8) 389.4 51.4 
(45.0-
57.7) 
373 49.2 
(44.2-
54.2) 
42.7 (38.1-47.3) 352 46.4 
(41.6-
51.3) 
39.7 (35.3-44.0) 
Male 17 4.7 (2.7-
7.5) 
3.7 (2.2-6.0) 22.9 6.3 (3.2-
9.4) 
23 6.3 (4.0-
9.5) 
5.3 (3.3-8.0) 24 6.6 (4.2-
9.8) 
5.3 (3.4-7.8) 
Female 290 73.4 
(64.9-
81.8) 
64.3 (56.4-72.2) 366.5 92.7 
(83.4-
102.1) 
350 88.6 
(79.3-
97.8) 
78.2 (69.4-86.9) 328 83.0 
(74.0-
92.0) 
72.0 (63.7-80.4) 
Non-
Hispanic 
Black 
282 131.4 
(116.1-
146.8) 
124.9 (110.3-
139.6) 
285.6 133.1 
(130.6-
135.7) 
326 151.9 
(135.5-
168.4) 
144.7 (128.9-
160.5) 
312 145.4 
(129.3-
161.6) 
137.7 (122.3-
153.1) 
Male 28 28.5 
(18.9-
41.2) 
26.7 (17.7-38.7) 28.0 28.5 
(28.1-
28.9) 
31 31.6 
(21.4-
44.8) 
29.7 (20.2-42.3) 24 24.4 
(15.7-
36.4) 
22.6 (14.5-33.7) 
Female 254 218.4 
(191.5-
245.2) 
210.9 (184.8-
237.1) 
257.6 221.4 
(217.1-
225.8) 
295 253.6 
(224.7-
282.5) 
244.4 (216.3-
272.6) 
288 247.6 
(219.0-
276.2) 
237.2 (209.5-
264.8) 
Hispanic 344 84.2  
(75.3-
93.1)  
82.8 (74.0-91.7) 345.4 84.6 
(83.8-
85.3) 
372 91.1 
(81.8-
100.3) 
90.2 (81.0-99.5) 396 97.0 
(87.4-
106.5) 
96.2 (86.7-
105.8) 
Male 38 19.7 
(13.9-
27.0)  
19.4 (13.6-26.9) 38.1 19.7 
(19.4-
20.0) 
38 19.7 
(13.9-
27.0) 
19.5 (13.7-26.9) 33 17.1 
(11.8-
24.0) 
16.7 (11.4-23.6) 
Female 306 142.1 
(126.2-
158.0)  
138.3 (122.7-
153.9) 
307.3 142.7 
(141.5-
143.9) 
334 155.1 
(138.4-
171.7) 
151.7 (135.3-
168.1) 
363 168.5 
(151.2-
185.9) 
165.3 (148.2-
182.5) 
Non-
Hispanic 
Asian 
111 64.0 
(52.1-
75.9)  
56.2 (44.7-67.7) 131.0 75.5 
(66.0-
85.0) 
145 83.6 
(70.0-
97.2) 
75.1 (61.7-88.5) 118 68.0 
(55.7-
80.3) 
62.2 (49.7-74.6) 
Male 15 19.3 
(10.8-
31.9)  
14.2 (7.6-24.0) 17.3 22.3 
(17.0-
27.6) 
15 19.3 
(10.8-
31.9) 
14.2 (7.6-24.0) 13 16.8 
(8.9-
28.7) 
12.5 (6.2-22.6) 
Female 96 100.0 
(81.0-
122.2) 
91.2 (72.1-
113.8) 
113.7 118.5 
(105.6-
131.3) 
130 135.5 
(112.2-
158.7) 
125.9 (102.0-
149.9) 
105 109.4 
(88.5-
130.3) 
103.6 (81.5-
125.8) 
Non-
Hispanic 
Other 
34   49.0  51   78   
Case definitions: ACR: meet ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE; SLICC: have sufficient criteria to meet 
the Systemic Lupus Erythematosus Collaborating Clinics (SLICC) classification; Rheumatologist: have been diagnosed with SLE by a treating 
rheumatologist  
Rates are per 100,000 Manhattan resident person-years. Denominator data is based on 2007 intercensal population estimates from the NYC 
DOHMH Bureau of Epi Services (2000-2014 files). Data are agestandardized for age and race/ethnicity adjusted to the US 2000 Standard 
Population.  
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Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-Hispanic black, non-Hispanic Asian, 
Hispanic, and non-Hispanic other. Non-Hispanic cases identified with more than one race were categorized as non-Hispanic other.   
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Table 2: Frequency of 11 ACR manifestations of SLE among prevalent and incident cases by the ACR case definition, 
overall and by race/ethnicity 
 Prevalent cases (2007) Incident cases (2007-2009) 
 Overall Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Hispanic Non-
Hispanic 
Asian 
Overall Non-
Hispanic 
White 
Non-
Hispanic 
Black 
Hispanic Non-
Hispanic 
Asian 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Overall 1,078 307 
(28.5) 
282 
(26.2) 
344 
(31.9) 
111 
(10.3) 
232 92 
(39.7) 
62 
(26.7) 
49 
(21.1) 
22 (9.5) 
Antinuclear 
antibody 
 
996 
(92.4) 
284 
(92.5) 
262 
(92.9) 
316 
(91.9) 
103 
(92.8) 
213 
(91.8) 
82 
(89.1) 
58 
(93.5) 
47 
(95.9) 
22 
(100.0) 
Hematologic 
disorder 
 
893 
(82.8) 
255 
(83.1) 
238 
(84.4) 
278 
(80.8) 
98 
(88.3) 
188 
(81.0) 
71 
(77.2) 
56 
(90.3*) 
37 
(75.5) 
19 
(86.4) 
Arthritis 813 
(75.4) 
 
246 
(80.1) 
204 
(72.3) 
255 
(74.1) 
80 
(72.1) 
159 
(68.5) 
66 
(71.7) 
41 
(66.1) 
30 
(61.2) 
17 
(77.3) 
Immunologic 
disorder 
 
781 
(72.4) 
213 
(69.4) 
204 
(72.3) 
253 
(73.5) 
89 
(80.2*) 
170 
(73.3) 
66 
(71.7) 
46 
(74.2) 
37 
(75.5) 
18 
(81.8) 
Renal 
disorder 
 
457 
(42.4) 
 
78 
(25.4) 
143 
(50.7*) 
170 
(49.4*) 
59 
(53.2*) 
81 
(34.9) 
22 
(23.9) 
27 
(43.5*) 
21 
(42.9*) 
10 
(45.5*) 
Serositis 449 
(41.7) 
 
117 
(38.1) 
127 
(45.0) 
156 
(45.3) 
36 
(32.4) 
84 
(36.2) 
25 
(27.2) 
33 
(53.2*) 
18 
(36.7) 
5 (22.7) 
Malar rash 428 
(39.7) 
 
110 
(35.8) 
82 
(29.1) 
172 
(50.0*) 
46 
(41.4) 
86 
(37.1) 
31 
(33.7) 
20 
(32.3) 
22 
(44.9) 
8 (36.4) 
Photo 
sensitivity 
370 
(34.3) 
 
121 
(39.4) 
76 
(27.0*) 
132 
(38.4) 
30 
(27.0*) 
74 
(31.9) 
32 
(34.8) 
11 
(17.7*) 
21 
(42.9) 
7 (31.8) 
Oral ulcers 333 
(30.9) 
 
104 
(33.9) 
64 
(22.7*) 
115 
(33.4) 
37 
(33.3) 
81 
(34.9) 
42 
(45.7) 
16 
(25.8*) 
12 
(24.5*) 
7 (31.8) 
Neurologic 
disorder 
230 
(21.3) 
 
51 
(16.6) 
69 
(24.5*) 
90 
(26.2*) 
11 (9.9) 43 
(18.5) 
15 
(16.3) 
15 
(24.2) 
11 
(22.4) 
1 (4.5) 
Discoid rash 179 
(16.6) 
 
27 (8.8)  73 
(25.9*) 
58 
(16.9*) 
17 
(15.3) 
32 
(13.8) 
9 (9.8) 16 
(25.8*) 
5 (10.2) 1 (4.5) 
ACR case definition: meets ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE.  
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-Hispanic black, 
non-Hispanic Asian, Hispanic, and non-Hispanic other. Non-Hispanic cases identified with more than one race were 
categorized as non-Hispanic other.  
* Univariate logistic regression indicates the proportion with this manifestation is significantly different than the proportion 
among non-Hispanic whites (p<0.05).            
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Table 3: Crude and age-adjusted standardized incidence rates of SLE among Manhattan residents, 2007-2009, according to the 
ACR, SLICC, and rheumatologist case definitions overall and by race/ethnicity and sex  
 ACR  SLICC Rheumatologist 
N Crude 
rate 
(95% 
CI) 
Age-
adjusted 
standardized 
rate (95% 
CI) 
Capture-recapture  N Crude 
rate 
(95% 
CI) 
Age-
adjusted 
standardized 
rate (95% 
CI) 
N Crude 
rate 
(95% 
CI) 
Age-
adjusted 
standardized 
rate (95% 
CI) 
N missed Adjusted 
rate (95% 
CI) 
Overall 232 4.9 
(4.3-
5.5) 
4.6 (4.0-5.2) 284.4 6.0 (4.6-
7.4) 
312 6.6 
(5.8-
7.3) 
6.2 (5.5-6.9) 253 5.3 
(4.7-
6.0) 
5.0 (4.4-5.7) 
Male 23 1.0 
(0.7-
1.5) 
1.0 (0.6-1.5) 26.3 1.2 (0.7-
1.7) 
38 1.7 
(1.2-
2.3) 
1.7 (1.2-2.3) 28 1.3 
(0.8-
1.8) 
1.2 (0.8-1.8) 
Female 209 8.3 
(7.2-
9.4) 
7.9 (6.8-9.0) 258.1 10.3 (8.0-
12.5) 
274 10.9 
(9.6-
12.2) 
10.3 (9.1-
11.6) 
225 8.9 
(7.8-
10.1) 
8.6 (7.4-9.7) 
Non-
Hispanic 
White 
92 4.0 
(3.2-
4.9) 
3.6 (2.8-4.5) 128.7 5.6 (4.2-
7.1) 
124 5.4 
(4.5-
6.4) 
4.8 (3.9-5.8) 94 4.1 
(3.3-
5.0) 
3.8 (3.0-4.8) 
Male 7 0.6 
(0.3-
1.3) 
0.5 (0.2-1.0) 8.6 0.8 (0.4-
1.2) 
13 1.2 
(0.6-
2.0) 
1.0 (0.5-1.7) 9 0.8 
(0.4-
1.6) 
0.7 (0.3-1.3) 
Female 85 7.1 
(5.7-
8.8) 
6.5 (5.0-8.3) 120.1 10.1 (7.7-
12.5) 
111 9.3 
(7.6-
11.1) 
8.5 (6.7-
10.3) 
85 7.1 
(5.7-
8.8) 
6.8 (5.2-8.6) 
Non-
Hispanic 
Black 
62 9.8 
(7.5-
12.6) 
9.3 (7.1-
12.0) 
63.8 10.1 (9.1-
11.0) 
79 12.5 
(9.9-
15.5) 
12.0 (9.5-
15.0) 
61 9.6 
(7.4-
12.4) 
9.2 (7.0-
11.8) 
Male 7 2.4 
(1.0-
5.0) 
2.4 (1.0-5.0) 8.0 2.8 (1.6-
3.9) 
11 3.8 
(1.9-
6.8) 
3.8 (1.9-6.8) 7 2.4 
(1.0-
5.0) 
2.3 (0.9-4.7) 
Female 55 16.0 
(12.1-
20.9) 
15.7 (11.8-
20.5) 
55.8 16.3 (15.5-
17.0) 
68 19.8 
(15.4-
25.1) 
19.3 (14.9-
24.5) 
54 15.7 
(11.8-
20.5) 
15.5 (11.6-
20.3) 
Hispanic 49 4.0 
(3.0-
5.3) 
4.0 (3.0-5.4) 50.3 4.1 (3.8-
4.5) 
64 5.2 
(4.0-
6.7) 
5.3 (4.1-6.7) 50 4.1 
(3.0-
5.4) 
4.2 (3.1-5.5) 
Male 7 1.2 
(0.5-
2.5) 
1.3 (0.5-2.7) 7.4 1.3 (1.0-
1.5) 
8 1.4 
(0.6-
2.7) 
1.6 (0.7-3.2) 6 1.0 
(0.4-
2.3) 
1.1 (0.4-2.5) 
Female 42 6.5 
(4.7-
8.8) 
6.5 (4.7-8.8) 42.9 6.7 (6.2-
7.1) 
56 8.7 
(6.6-
11.3) 
8.6 (6.5-
11.2) 
44 6.8 
(5.0-
9.2) 
7.0 (5.1-9.4) 
Non-
Hispanic 
Asian 
22 4.2 
(2.6-
6.3) 
3.8 (2.3-6.0) 28.7 5.4 (3.3-
7.5) 
31 5.8 
(4.0-
8.3) 
5.3 (3.4-7.7) 27 5.1 
(3.4-
7.4) 
4.5 (2.9-6.9) 
Male 1 0.4 
(0.0-
2.4) 
0.5 (0.0-2.7) 1.3 0.6 (0.0-
1.1) 
2 0.8 
(0.1-
3.1) 
1.0 (0.1-3.5) 2 0.8 
(0.1-
3.1) 
1.0 (0.1-3.7) 
Female 21 7.1 
(4.4-
10.9) 
6.6 (3.8-
10.5) 
27.4 9.3 (6.0-
12.7) 
29 9.9 
(6.6-
14.2) 
8.8 (5.6-
13.1) 
25 8.5 
(5.5-
12.6) 
7.5 (4.5-
11.6) 
Non-
Hispanic 
Other 
7   12.9  14   21   
Case definitions: ACR: meet ≥ 4 of 11 American College of Rheumatology (ACR) classification criteria for SLE; SLICC: have 
sufficient criteria to meet the Systemic Lupus Erythematosus Collaborating Clinics (SLICC) classification; Rheumatologist: have 
been diagnosed with SLE by a treating rheumatologist    
Rates are per 100,000 Manhattan resident person-years. Denominator data is based on 2007-2009 intercensal population 
estimates from the NYC DOHMH Bureau of Epi Services (2000-2014 files). Data are agestandardized  for age and race/ethnicity 
adjusted to the US 2000 Standard Population.  
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Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-Hispanic white, non-Hispanic black, non-
Hispanic Asian, Hispanic, and non-Hispanic other. Non-Hispanic cases identified with more than one race were categorized as 
non-Hispanic other.   
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Table 4: Unique manifestations among SLE incident and prevalent cases meeting SLICC but not ACR case definitions 
 N % 
Overall  310  
Immunologic criteria   
    Low complements 151 48.7% 
    Anti-Beta2 Glycoprotein Antibodies (IgG, or IgM)bs 16 5.2% 
    Direct Coombs test in the absence of hemolytic anemia 5 1.6% 
   
Clinical critiriacriteria   
Acute cutaneous lupus   
    Bullous lupus 1 0.3% 
    Toxic epidermal neocrolysis variant of SLE  0 0.0% 
    Maculopapular lupus rash (only if Malar) 13 4.2% 
    Subacute cutaneous lupus  4 1.3% 
Chronic cutaneous lupus   
    Hypertrophic (verrucous) lupus 3 1.0% 
    Lupus Panniculitis (profundus) 4 1.3% 
    Mucosal lupus if oral ulcers 0 0.0% 
    Lupus erythematosus tumidus 1 0.3% 
    Chilblains lupus 1 0.3% 
    Discoid lupus/Lichen planus overlap 4 1.3% 
Non-scarring alopecia 122 39.4% 
Neurologic criteria   
    Mononeuritis multiplex 3 1.0% 
    Transverse mMyelitis 2 0.6% 
    Peripheral or cranial neuropathy 53 17.1% 
    Acute cConfusional Sstate 3 1.0% 
Lymphopenia 147 47.4% 
 
Antinuclear antibody or anti-double stranded DNA and biopsy proven 
lupus nephritis and renal biopsy only 
17 5.5% 
SLICC: Systemic Lupus Erythematosus Collaborating Clinics  
ACR: American College of Rheumatology 
Criteria are not mutually exclusive; a case may have more than one criteria listed above.    
Data on IgA isotypes for anti–B2glycoprotein I and anti-cardiolipin antibodies were not collected. Anti-dsDNA when done 
by ELISA was only reported as positive or negative so it is possible that is some cases this criterion was over counted in 
the SLICC if the positive was not specifically double the upper cutoff for the negative value. Finally, CH50 was not 
captured and thus it is possible that the SLICC criterion for complement could be under-counted. 
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Figure 1. Flow chart showing the Manhattan Lupus Surveillance Program case-
finding procedure for Systemic Lupus Erythematosus  
 
ACR case definition: meet ≥ 4 of 11 American College of Rheumatology (ACR) 
classification criteria for SLE 
SLICC case definition: have sufficient criteria to meet the Systemic Lupus 
Erythematosus Collaborating Clinics (SLICC) classification 
Rheumatologist definition: have been diagnosed with SLE by a treating rheumatologist 
 
  
Figure 2. Age-specific prevalence and incidence rates of SLE among Manhattan 
residents in 2007 and from 2007-2009 by ACR case definition, by age group 
among females 
 
ACR case definition: meets ≥ 4 of 11 American College of Rheumatology (ACR) 
classification criteria for SLE 
Cases were assigned to one of five mutually exclusive race/ethnicity categories: non-
Hispanic white, non-Hispanic black, non-Hispanic Asian, Hispanic, and non-Hispanic 
other.  
Non-Hispanic cases identified with more than one race were categorized as non-
Hispanic other and are not shown in this figure. 
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